References
- Brown J.M. Hypoxic cell radiosensitizers: Where next?. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 987–993
- Chaplin D.J., Horsman M.R., Trotter M.J. The effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. Journal of the National Cancer Institute 1990; 82: 672–676
- Coleman C.N., Wasserman T.H., Urtasun R.C., Halsey J., Noll L., Hancock S., Phillips T.L. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03. International Journal of Radiation Oncology, Biology, Physics 1990; 18: 389–393
- Dische S., Saunders M.I., Dunphy E.P., Bennett M.H., Des R.C., Stratford M.R., Minchinton A.I., Orchard R.A. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1109–1111
- Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H., Broder G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. International Journal of Radiation Oncology, Biology, Physics 1988; 14: 831–838
- Horsman M.R., Brown D.M., Lemmon M.J., Brown J.M., Lee W.W. Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1307–1310
- Horsman M.R., Brown J.M., Hirst V.K., Lemmon M.J., Wood P.J., Dunphy E.P., Overgaard J. Mechanism of action of the selective tumor radiosensitizer nicotinamide. International Journal of Radiation Oncology, Biology, Physics 1988; 15: 685–690
- Horsman M.R., Chaplin D.J., Brown J.M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiation Research 1987; 109: 479–489
- Horsman M.R., Chaplin D.J., Brown J.M. Tumor radiosensitization by nicotinamide: a result of improved blood perfusion and oxygenation. Radiation Research 1989; 118: 139–150
- Horsman M.R., Evans J.W., Brown J.M. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms. British Journal of Cancer 1984; 50: 305–316
- Jonsson G.G., Kjellen E., Pero R.W. Nicotinamide as a radiosensitizer of a C3H mouse mammary adenocarcinoma. Radiotherapy and Oncology 1984; 1: 349–353
- Kjellen E., Pero R.W., Nilsson P. Comparison of low dose nicotinamide versus benzamide, administered per os, as radiosensitizers in C3H mammary carcinoma. Radiotherapy and Oncology 1988; 12: 327–331
- Morisawa U., Kataoka M., Kitano N., Matsuzawa T. Studies on anticoccidial agents. 10. Synthesis and anticoccidial activity of nitronicotinamide and its analogues. Journal of Medicinal Chemistry 1977; 20: 129–133
- Nickerson M. Vasodilator drugs. The Pharmacological Basis of Therapeutics, L.S. Goodman, A. Gilman. Macmillan, New York 1975; 727–743
- Okunieff P., Kallinowski F., Vaupel P., Neuringer L.J. Effects of hydralazine-induced vasodilation of the energy metabolism of murine tumors studied by in vivo P-nuclear magnetic resonance spectroscopy. Journal of the National Cancer Institute 1988; 80: 745–750
- Purnell M.R., Whish W.J.D. Novel inhibitors of poly (ADP-ribose) synthetase. Biochemical Journal 1980; 185: 775–777
- Shall S. ADP-ribose in DNA repair. ADP-Ribosylation Reactions, Biology and Medicine, O. Hayashi, K. Veda. Academic Press, New York 1982; 477–520
- Shtacher G., Erez M., Cohen S. Selectivity in new β-adrenergic blocking agents. (3-amino-2-hydroxypropoxy)benzamides. Journal of Medicinal Chemistry 1973; 16: 516–519
- Winter S.L., Boyer J.L. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). New England Journal of Medicine 1973; 289: 1180–1182
- Zackheim H.S., Vasily D.B., Westphal M.L., Hastings C.W. Reactions to niacinamide. Journal of the American Academy of Dermatology 1981; 4: 736–737